Metrotex

Quick links to important sections

Metrotex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metrotex

Property Description
Active Ingredient Methotrexate (MTX)
Form Tablet, Solution for Injection, Oral Solution
Pharmacological Class Immunosuppressant, Antimetabolite
Common Use Systemic inflammatory diseases, Neoplastic disease
Origin Synthetic (Folate Analogue)

Metrotex is a trade name for the powerful synthetic drug Methotrexate (MTX), which is primarily classified as an antimetabolite and a potent immunosuppressant. This medication belongs to the category known as Disease-Modifying Antirheumatic Drugs (DMARDs), which are clinically recognized for their capacity to address the underlying mechanism of disease rather than simply managing symptoms. Methotrexate is structurally defined as a folate analogue that operates by interfering with certain metabolic processes within the body's cells. As a core cytotoxic agent, its use signifies a targeted, systemic approach to managing conditions where uncontrolled cell activity or an overactive immune response causes damage.

Composition, Form, and Therapeutic Purpose

The composition of Metrotex is based on a single-ingredient product, containing only the active compound Methotrexate. This systemic therapy is available in several dosage forms to suit different clinical needs, including the traditional tablet for oral use and a sterile solution for injection or oral solution. Whether in solid or liquid form, the active ingredient is combined with appropriate pharmaceutical excipients or a sterile aqueous vehicle, ensuring safe and effective delivery for oral or parenteral administration.

The general therapeutic purpose of a folic acid antagonist like Methotrexate is to modulate the immune system and control cellular proliferation. By acting as an antimetabolite, the drug interferes with the necessary synthesis of DNA and RNA, which is essential for rapidly dividing cells. This fundamental action provides the general benefit of reducing tissue destruction caused by uncontrolled cell activity in neoplastic disease and mitigating the chronic, destructive inflammation that drives severe systemic inflammatory diseases and autoimmune disorders. For instance, it is a foundation of treatment for patients with severe, active rheumatoid arthritis, where its immunomodulation effect is essential for preserving joint function.

Regulatory References

  1. Methotrexate Chemical Definition (NCI)

What side effects are possible with Metrotex?

The active ingredient in Metrotex, Methotrexate, is associated with a range of documented adverse reactions that are formally classified by frequency and physiological system in government regulatory documents. Because of the potential for severe, sometimes fatal, toxic reactions, continuous monitoring of various organ systems is required throughout treatment.

Classified Adverse Reactions and Organ Systems

Official regulatory documentation classifies adverse reactions into system-organ classes, with Gastrointestinal Disorders and Blood and Lymphatic System Disorders being frequently observed categories. Reactions are categorized by frequency:

  • Very Common and Common Reactions often include leukopenia, stomatitis (mouth sores), nausea, abdominal discomfort, and transient elevations in liver function tests.
  • Serious Organ-Specific Toxicities include potentially fatal myelosuppression (bone marrow suppression), severe pulmonary toxicity (interstitial pneumonitis) which can occur at any time, and life-threatening hepatotoxicity (fibrosis/cirrhosis) associated with prolonged use.

Population-Specific and Contextual Safety Constraints

The safety profile includes constraints for specific populations and circumstances. Methotrexate is explicitly listed as a teratogen, capable of causing fetal death and is contraindicated during pregnancy for non-neoplastic indications. Patients with renal or hepatic impairment are at increased risk of severe toxicity due to impaired drug clearance.

Regulatory safety notes document that drug elimination is reduced in patients with pathological fluid accumulation (e.g., ascites), leading to an increased risk of toxicity. Additionally, the risk of severe toxicity, including myelosuppression, is documented to increase when Methotrexate is used concurrently with certain other agents, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Overdose and Emergency Response

Overdose and When to Seek Help

Metrotex (methotrexate) toxicity is a serious medical event that can be life-threatening and requires immediate attention.

Overdose often results in severe toxicity, most commonly affecting the rapidly dividing cells in the body, such as those in the bone marrow and the lining of the gastrointestinal tract. This risk is notably increased by medication errors, particularly when the drug is mistakenly taken daily instead of the prescribed once-weekly schedule for conditions like rheumatoid arthritis or psoriasis.

Primary Overdose Manifestations
Hematologic: Severe decrease in blood cell production, including leukopenia, thrombocytopenia, and pancytopenia.
Gastrointestinal: Mucositis, stomatitis, ulcers in the mouth, nausea, vomiting, or severe diarrhea, which can progress to hemorrhagic enteritis and intestinal perforation.
Other Severe Effects: Renal failure, sepsis, or septic shock. Intrathecal (spinal) overdosage may cause nervous system symptoms like seizures.

Urgent Medical Attention Required

If you suspect an overdose, or if any of the following severe symptoms appear, seek emergency medical help immediately:

  • Severe diarrhea or vomiting
  • Mouth sores or ulcers (stomatitis) that are new or worsening
  • Signs of infection, such as fever, chills, or persistent sore throat
  • Unusual bruising, bleeding, or paleness

Specific medical interventions, such as the use of the antidotes leucovorin or glucarpidase, or aggressive hydration and urinary alkalinization, are necessary to mitigate toxicity and counteract the effects of high drug levels.

Therapeutic Uses of Metrotex

What Metrotex Treats: Main Uses and Benefits

Metrotex (Methotrexate) is generally used in clinical settings that involve acute or unstable symptom patterns driven by systemic imbalance or heightened cellular activity. It is considered relevant when supportive symptom management is appropriate, particularly in clinical contexts involving heightened systemic burden. The medication is applied across domains where additional symptomatic support is needed for a wide range of conditions marked by increased physiological stress.

The medication is commonly used to help with Systemic Inflammatory and Autoimmune Disorders such as severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA), as well as severe Psoriasis and certain Neoplastic Diseases. The therapeutic benefit is often linked to managing symptom clusters that become intense, like chronic joint pain and swelling that interfere with daily functioning, and skin symptoms related to inflammatory or irritative states. This supportive relief helps patients cope more steadily with difficult episodes.


Quick Fact: Supportive Relief for Inflammatory Joint Symptoms

The use of Metrotex may assist with managing the progression of the underlying disease and provides supportive relief when symptoms become temporarily overwhelming.

Regulatory References

  1. NIH MedlinePlus Drug Information Overview

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adult and pediatric patients for various labeled conditions, including Rheumatoid Arthritis, Severe Psoriasis, Polyarticular Juvenile Idiopathic Arthritis, and several Neoplastic Diseases.

Populations for whom use is contraindicated:

  • Pregnant Women (for non-neoplastic diseases) and nursing mothers.
  • Patients with a history of severe hypersensitivity to the drug.
  • Individuals with severe renal impairment (creatinine clearance <30 ml/min), alcoholic or chronic liver disease, pre-existing blood dyscrasias, immunodeficiency syndromes, or severe acute infections.

Age-related eligibility rules: Use is generally not recommended for children under 3 years old. Geriatric patients require caution and may need dose adjustments due to age-related organ function decline. Use in neonates is restricted to preservative-free formulations only.

Pregnancy and lactation eligibility status: The medicine is contraindicated in pregnancy for non-neoplastic use. Effective contraception is mandatory for both males and females of reproductive potential during and for a specified period after therapy.

Connection to the overall eligibility profile

Official regulatory documents establish stringent eligibility criteria, primarily prohibiting use based on the patient’s existing physiological state. These rules mandate absolute exclusion for populations defined as high risk, such as pregnant women (for non-neoplastic use) and those with severely compromised liver or kidney function or pre-existing bone marrow disorders. This regulatory framework defines precisely who can and cannot receive the medicine.

What should I know about interactions with other medicines?

The official interaction profile for Metrotex is defined by agents that can elevate its concentration in the body or increase the risk of specific toxicities. These statements are derived from official regulatory documents (e.g., FDA, EMA) and are critically important for patient safety.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Product Category Interaction Mechanism and Constraint Classification
NSAIDs and Salicylates (e.g., Aspirin, Ibuprofen) Reduce Methotrexate's renal clearance (elimination), causing elevated plasma levels. This combination requires careful monitoring, especially with high-dose Methotrexate, where it is often avoided or used with extreme caution. Serious/High Risk
Trimethoprim/Sulfamethoxazole Causes additive antifolate effects and may reduce renal clearance. This combination is associated with severe, sometimes fatal, myelosuppression and is often avoided or contraindicated. Serious/Contraindicated
Penicillins (e.g., Amoxicillin) May reduce Methotrexate's renal tubular secretion, leading to increased serum concentrations and a risk of toxicity. Careful monitoring is required for hematologic and gastrointestinal side effects. Use with Caution
Proton Pump Inhibitors (PPIs) (e.g., Omeprazole) May decrease Methotrexate elimination, leading to elevated levels. This interaction is particularly relevant at high Methotrexate doses, where co-administration is discouraged. Serious/High Risk
Highly Protein-Bound Drugs (e.g., Phenytoin, Sulfonamides) May displace Methotrexate from plasma proteins, increasing the concentration of unbound, active drug and the potential for toxicity. Use with Caution
Hepatotoxic Agents (e.g., Alcohol) Use with other agents known to cause liver injury is restricted due to the additive risk of hepatotoxicity (liver damage). Use with Caution

These official constraints establish that combinations that impair renal function or add to folate antagonism present the greatest risk and require the most stringent clinical constraints or avoidance.

Mechanism of Action

Metabolic Inhibition and Cell Cycle Suppression

Methotrexate (MTX) acts as a folate antagonist, primarily by competitively inhibiting the enzyme Dihydrofolate Reductase (DHFR). This molecular block deprives rapidly dividing cells of the necessary reduced folates for DNA and RNA synthesis, resulting in a cytotoxic and antiproliferative effect. This mechanism restricts the activity of high-turnover cell populations by arresting the cell cycle.

Indirect Immunomodulation via Adenosine Signaling

Beyond its metabolic role, MTX's active polyglutamated forms inhibit the enzyme ATIC (Aminoimidazole-4-carboxamide Ribonucleotide Transformylase), leading to an accumulation and subsequent release of the signaling molecule adenosine into the local environment. This adenosine then acts on specific cell-surface receptors (A2A, A3) on immune cells, initiating an inhibitory signal that suppresses the release of pro-inflammatory mediators. This results in the modulation of inflammatory signaling and immune cell activity.

Mechanistic Duality and Onset Constraints

The full modulation of inflammatory signaling is achieved only after the drug is converted into its active forms inside the cell—a process that requires time. This physiological constraint explains the delayed onset of action associated with the immunomodulatory domain.

Dosage and Administration Information

Route and Formulation

Metrotex (Methotrexate) is administered using multiple approved routes, depending on the clinical context and formulation. It is available as an oral tablet or solution, and as a solution for injection. The approved parenteral routes include intramuscular (IM), subcutaneous (SC), and intravenous (IV) administration. Specialized applications, such as the intrathecal route, require the exclusive use of preservative-free formulations. Oral solutions and tablets are typically swallowed whole and may generally be taken with or without food.


Frequency and Dosing Regimens

The fundamental usage principle for non-neoplastic diseases, such as Rheumatoid Arthritis and Psoriasis, is once-weekly dosing. This frequency is critical, and the prescribing physician must specify the exact day of intake to prevent the serious risk associated with accidental daily administration. For adult Rheumatoid Arthritis, the starting dose is commonly 7.5 mg once weekly and is subject to gradual dose escalation up to the established maximum maintenance doses. Pediatric dosing, such as for Juvenile Idiopathic Arthritis, is calculated based on the patient’s Body Surface Area (BSA).


Procedural Constraints

Administration of Metrotex must occur under the supervision of physicians with experience in antimetabolite therapy. Dose modification or discontinuation is required for patients with renal or hepatic impairment, as the drug is cleared primarily through these systems. Similarly, lower doses and close monitoring are advised for the older adult population.

Recent Clinical Evidence

Metrotex: Recent Clinical Evidence

This section summarizes the official research evidence for Methotrexate (Metrotex), focusing on the types of clinical studies conducted and the overall patterns described in scientific literature. Research examines how this medication was evaluated in specific health conditions, but this information is not personal medical advice. We will outline what studies monitored, what findings indicate, and where the evidence is limited or certainty remains low.

Evidence for Use in Systemic Inflammatory Conditions

Research related to Metrotex for severe Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) stems primarily from formal clinical trials and comprehensive analyses. For RA, the research base is extensive, including Randomized Controlled Trials (RCTs) and Meta-analyses that tracked measures of disease activity and patient-reported outcomes. Long-term observational cohort studies monitored treatment persistence over extended periods. For PsA and severe Psoriasis, the evidence relies more on Observational Studies and limited RCTs. Scientific reviews often note that the evidence quality varies across studies, and certainty remains low due to the lack of numerous large-scale RCTs specifically for PsA.

Evidence for Use in Neoplastic Diseases

Metrotex was studied for use in highly specific neoplastic diseases as part of complex chemotherapy protocols. The research structure is based on Phase I, II, and III Clinical Trials and retrospective analyses that examined specific types of cancer. Research examined clinical outcomes such as Overall Survival (OS) and Complete Response (CR) rates. Because the medicine is generally evaluated as one component within multi-drug chemotherapy regimens, comparative evidence is lacking for the isolated contribution of the single agent, meaning subgroup findings are uncertain.

Long-Term Studies and Research Uncertainty

For systemic inflammatory conditions, long-term effects are not fully established by RCTs; instead, long-term monitoring was observed in large observational settings. Data for certain groups remain insufficient, particularly concerning the systematic evaluation of older adults or those with complex existing health conditions (comorbidities) within controlled trials. Across all indications, a common limitation described in the literature is the number of patients who stop treatment due to reasons observed during the study.

Key Studies & References

  1. Methotrexate: MedlinePlus Drug Information (Covers FDA/General Indications for Cancer, RA, Psoriasis)

Frequently Asked Questions (FAQ)

Common questions about Metrotex (FAQ)


Q: Is Metrotex the same kind of drug as [Similar Drug Name]?

Metrotex (Methotrexate) is formally classified as an antimetabolite and is often described as a Disease-Modifying Antirheumatic Drug (DMARD) for inflammatory conditions. This classification indicates that its actions involve interfering with certain cell processes and helping to modulate the immune system to slow disease progression. While other medicines may also be DMARDs, Metrotex’s specific mechanism is based on its structure as a folate antagonist.


Q: What are the most common concerns people express about Metrotex online?

Official documents indicate that frequently reported reactions often involve certain side effects classified as very common or common. The most frequent concerns often include gastrointestinal issues such as nausea and abdominal discomfort, as well as mouth sores (stomatitis). Temporary elevations in liver function tests are also commonly noted.


Q: Are there different forms of Metrotex (e.g., tablets, injection)?

Yes, Metrotex is available in different forms to suit various clinical needs. The approved forms include an oral tablet, an oral solution, and a sterile solution for injection. The solution for injection is approved for several routes of administration, including subcutaneous (under the skin), intramuscular (into the muscle), and intravenous (into the vein).


Q: How is Metrotex processed by the body (metabolism)?

Metrotex is processed inside the body’s cells, where it is converted into polyglutamated forms that are biologically active. The elimination of the drug happens primarily through the kidneys (renal clearance) and, to a lesser extent, through biliary excretion (via the liver). This clearance process underscores the need for continuous monitoring of kidney and liver function as described in official guidelines.


Q: Does Metrotex cause hair loss?

Official regulatory documents list hair loss (alopecia) as a possible side effect of Metrotex. It is typically documented as an uncommon reaction, meaning it occurs in a small percentage of patients. If hair loss is observed, official reports generally describe it as reversible upon discontinuation.


Q: Is a prescription required for Metrotex?

Yes, Metrotex is strictly a prescription-only medicine. Regulatory bodies worldwide require this due to the drug’s potent nature and the risk of serious complications, particularly due to the risk associated with incorrect daily dosing instead of the specified weekly frequency. Official documents mandate that the drug be prescribed only by physicians experienced in its use.


Q: Are headaches a commonly reported experience with Metrotex?

According to official patient information leaflets, headache is listed as a potential side effect. For inflammatory conditions, headache is frequently classified as a common reaction. If a person experiences headaches, it is generally considered one of the reactions that may occur with this medicine.


Q: Are there any known interactions between Metrotex and common vitamins or supplements?

Yes, an important consideration is the interaction with supplements containing folic acid or folinic acid. Because Metrotex works by interfering with how the body uses folate, taking high amounts of these supplements without medical guidance may reduce the intended therapeutic effect of the medicine. Information regarding any supplementation should be reviewed with a healthcare provider.


Q: Does Metrotex make people more sensitive to the sun?

Yes, official warnings advise that Metrotex may cause photosensitivity, which is an increased sensitivity of the skin to sunlight. This can result in a severe reaction similar to sunburn. Official guidance suggests that users should limit sun exposure and use sun protection while taking this medicine.


Q: Is Metrotex known by any other brand names globally?

Yes, the active ingredient, Methotrexate, is sold under numerous trade names in different countries. Examples of brand names found in regulatory and patient information sources include Jylamvo, Maxtrex, Methofill, Metoject, Nordimet, and Zlatal. Generic versions are also widely available.


Q: Are there any specific lifestyle changes mentioned in official documents when using Metrotex?

Official guidance strongly emphasizes the need to avoid or severely limit alcohol intake. This is due to the additive risk of hepatotoxicity (liver damage) when alcohol is consumed while using Metrotex. This restriction is consistently noted as a key safety constraint associated with the drug.


Q: Does Metrotex interact with oral contraceptives?

Based on general drug interaction checks in official information, Metrotex is not typically listed as directly affecting the effectiveness of oral contraceptive pills. However, severe side effects like vomiting or diarrhea, which are possible with Metrotex, could potentially compromise the absorption of any oral medication, including contraceptives.


Q: Is there a maximum time frame for which Metrotex is typically used?

For chronic inflammatory conditions, Metrotex is often prescribed as a long-term therapy. Official guidelines indicate that the total duration of treatment is generally not fixed but is assessed based on a patient's ongoing response and tolerance. Continuous monitoring of patients is part of the long-term use strategy.


Q: Does Metrotex help with pain relief, or does it only treat the underlying disease?

Metrotex is primarily a Disease-Modifying Antirheumatic Drug (DMARD), meaning its main function is to suppress the underlying disease process, such as inflammation and immune activity. By reducing the cause of the disease, it may consequently reduce associated symptoms such as pain, swelling, and morning stiffness related to the condition.


Q: What does official guidance say about driving or operating machinery while using Metrotex?

Official patient information advises caution regarding driving or operating machinery. Side effects such as dizziness, drowsiness, blurred vision, or fatigue are possible with Metrotex. Users are therefore cautioned to wait and see how the medicine affects them before engaging in activities that require focus and attention.


Q: Is there a black box warning associated with Metrotex in the US?

Yes. In the United States, official FDA documents include several Boxed Warnings (often called Black Box Warnings) for Metrotex. These are prominent warnings that highlight serious or potentially fatal toxic risks, including embryo-fetal death, severe damage to the liver, lungs, and bone marrow, and serious skin reactions.


Q: Are there dietary restrictions mentioned for people on Metrotex?

The most stringent restriction found in regulatory documentation is the severe limitation or avoidance of alcohol due to the risk of liver damage. Additionally, while not a restriction, intake of folic acid supplements is often managed under medical supervision. The oral tablet is generally described as being taken with or without food.

How should Metrotex be stored and disposed of?

Methotrexate must be stored at Controlled Room Temperature (20 C to 25 C), protecting the product from light and freezing. The medication must be kept in its original container and the container must be tightly closed.

Storage Classification Requirement
Temperature Controlled Room Temperature
Prohibited Do not freeze
Protection Protect from light; Keep tightly closed

Multi-dose injection vials containing a preservative must be stored under refrigeration (2 C to 8 C) after the first puncture and used within 30 days. Methotrexate is classified as a hazardous drug. Disposal of all unused product, including single-use contents, must follow special handling and disposal procedures for cytotoxic waste according to local regulations. The product must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Metrotex found in:

A-Z Index: